A detailed history of Black Rock Inc. transactions in Immunic, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 679,343 shares of IMUX stock, worth $801,624. This represents 0.0% of its overall portfolio holdings.

Number of Shares
679,343
Previous 661,254 2.74%
Holding current value
$801,624
Previous $872,000 13.53%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.98 - $1.44 $17,727 - $26,048
18,089 Added 2.74%
679,343 $754,000
Q1 2024

May 10, 2024

BUY
$1.14 - $1.53 $341,005 - $457,665
299,128 Added 82.6%
661,254 $872,000
Q4 2023

Feb 13, 2024

BUY
$0.97 - $1.6 $5,157 - $8,507
5,317 Added 1.49%
362,126 $543,000
Q3 2023

Nov 13, 2023

SELL
$1.35 - $2.87 $27,936 - $59,391
-20,694 Reduced 5.48%
356,809 $524,000
Q2 2023

Aug 11, 2023

BUY
$1.33 - $2.51 $12,051 - $22,743
9,061 Added 2.46%
377,503 $947,000
Q1 2023

May 12, 2023

BUY
$1.35 - $2.87 $2,299 - $4,887
1,703 Added 0.46%
368,442 $548,000
Q4 2022

Feb 13, 2023

SELL
$1.13 - $10.8 $112,771 - $1.08 Million
-99,798 Reduced 21.39%
366,739 $513,000
Q3 2022

Nov 14, 2022

SELL
$3.0 - $5.49 $15,342 - $28,075
-5,114 Reduced 1.08%
466,537 $1.48 Million
Q2 2022

Aug 12, 2022

SELL
$3.13 - $12.25 $2.64 Million - $10.3 Million
-842,833 Reduced 64.12%
471,651 $1.64 Million
Q1 2022

May 12, 2022

BUY
$9.54 - $14.26 $111,694 - $166,956
11,708 Added 0.9%
1,314,484 $14.9 Million
Q4 2021

Feb 10, 2022

BUY
$7.34 - $10.25 $378,971 - $529,217
51,631 Added 4.13%
1,302,776 $12.5 Million
Q3 2021

Nov 09, 2021

BUY
$8.05 - $13.29 $1.01 Million - $1.66 Million
124,852 Added 11.09%
1,251,145 $11.1 Million
Q2 2021

Aug 11, 2021

BUY
$11.76 - $16.85 $13.2 Million - $19 Million
1,126,293 New
1,126,293 $13.8 Million

Others Institutions Holding IMUX

About IMMUNIC, INC.


  • Ticker IMUX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,565,000
  • Market Cap $36.1M
  • Description
  • Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...
More about IMUX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.